Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Posted by Brian Himes on Sep 3rd, 2026

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $16.7143.

A number of research firms have commented on KRRO. JonesTrading upgraded Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Lifesci Capital raised Korro Bio to a “strong-buy” rating in a research note on Friday, May 29th. Wall Street Zen upgraded Korro Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Korro Bio in a research report on Thursday, August 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Korro Bio in a report on Monday, July 6th.

Get Our Latest Research Report on KRRO

Korro Bio Stock Performance

KRRO stock opened at $11.97 on Thursday. The company has a fifty day moving average price of $12.69 and a 200-day moving average price of $12.27. The company has a market capitalization of $176.32 million, a P/E ratio of -1.20 and a beta of 3.09. Korro Bio has a 52-week low of $5.20 and a 52-week high of $55.89.

Korro Bio (NASDAQ:KRRO – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.07) EPS for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.27. Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 114.26%. As a group, sell-side analysts forecast that Korro Bio will post -4.97 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Loic A. Vincent sold 3,418 shares of the stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $10.83, for a total transaction of $37,016.94. Following the completion of the sale, the insider directly owned 18,297 shares in the company, valued at $198,156.51. This represents a 15.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Todd Chappell sold 3,168 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $10.83, for a total transaction of $34,309.44. Following the completion of the transaction, the chief operating officer owned 16,964 shares in the company, valued at approximately $183,720.12. The trade was a 15.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 318,925 shares of company stock valued at $4,505,723. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its stake in Korro Bio by 10.8% during the second quarter. Geode Capital Management LLC now owns 155,387 shares of the company’s stock worth $1,941,000 after purchasing an additional 15,166 shares during the period. Raymond James Financial Inc. lifted its stake in Korro Bio by 357.6% in the second quarter. Raymond James Financial Inc. now owns 83,392 shares of the company’s stock valued at $1,042,000 after buying an additional 65,170 shares during the period. Bank of America Corp DE lifted its stake in Korro Bio by 520.0% in the second quarter. Bank of America Corp DE now owns 28,156 shares of the company’s stock valued at $352,000 after buying an additional 23,615 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Korro Bio by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 395,659 shares of the company’s stock worth $18,948,000 after buying an additional 8,921 shares in the last quarter. Finally, Blair William & Co. IL bought a new position in shares of Korro Bio during the 3rd quarter worth approximately $467,000. 13.18% of the stock is owned by institutional investors and hedge funds.

About Korro Bio

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.